A phase 1, randomized, open-label, active-controlled trial to assess the safety of a meningococcal serogroup B bivalent rLP2086 vaccine in healthy adults

References

• Christensen H, May M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10:853 - 61; http://dx.doi.org/10.1016/S1473-3099(10)70251-6; PMID: 21075057
   PubMed Web of Science ®Google Scholar
• Thompson MJ, Ninis N, Perera R, Mayon-White R, Phillips C, Bailey L, et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet 2006; 367:397 - 403; http://dx.doi.org/10.1016/S0140-6736(06)67932-4; PMID: 16458763
   PubMed Web of Science ®Google Scholar
• Bilukha OO, Rosenstein N, National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2005; 54:RR-7 1 - 21; PMID: 15917737
   PubMedGoogle Scholar
• Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10:317 - 28; http://dx.doi.org/10.1016/S1473-3099(10)70048-7; PMID: 20417414
   PubMed Web of Science ®Google Scholar
• Girard MP, Preziosi MP, Aguado MT, Kieny MP. A review of vaccine research and development: meningococcal disease. Vaccine 2006; 24:4692 - 700; http://dx.doi.org/10.1016/j.vaccine.2006.03.034; PMID: 16621189
   PubMed Web of Science ®Google Scholar
• Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 2009; 27:Suppl 2 B51 - 63; http://dx.doi.org/10.1016/j.vaccine.2009.04.063; PMID: 19477562
   PubMed Web of Science ®Google Scholar
• Zollinger WD, Boslego J. Immunologic Methods for Diagnosis of Infections by Gram-Negative Cocci. In: Rose NR, ed. Manual of clinical laboratory immunology. Washington, DC: ASM Press, 1997:473-83.
   Google Scholar
• Pace D, Pollard AJ, Messonier NE. Quadrivalent meningococcal conjugate vaccines. Vaccine 2009; 27:Suppl 2 B30 - 41; http://dx.doi.org/10.1016/j.vaccine.2009.05.003; PMID: 19477560
   PubMed Web of Science ®Google Scholar
• Trotter CL, Ramsay ME, Kaczmarski EB. Meningococcal serogroup C conjugate vaccination in England and Wales: coverage and initial impact of the campaign. Commun Dis Public Health 2002; 5:220 - 5; PMID: 12434692
   PubMedGoogle Scholar
• United Kingdom Health Protection Agency. Meningococcal Reference Unit: Isolates of Neisseria menengitidis; England and Wales, by serogroup & calendar year, 1998-2010*. 2010: http://www.hpa.org.uk/web/HPAweb&HPAwebStandard/HPAweb_C/1234859712887. Accessed February 2012.
   Google Scholar
• de Greeff SC, de Melker HE, Spanjaard L, Schouls LM, van Derende A. Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands. Pediatr Infect Dis J 2006; 25:79 - 80; http://dx.doi.org/10.1097/01.inf.0000195594.41449.c6; PMID: 16395110
   PubMed Web of Science ®Google Scholar
• Slinko VG, Sweeny A. Reduction in invasive meningococcal disease in Queensland: a success for immunisation. Commun Dis Intell 2007; 31:227 - 32; PMID: 17725000
   PubMedGoogle Scholar
• Australian Meningococcal Surveillance Programme. Annual report of the Australian Meningococcal Surveillance Programme, 2009. Commun Dis Intell 2010; 34:291 - 302; PMID: 21090184
   PubMedGoogle Scholar
• van Driel JJ, Bekker V, Spanjaard L, van der Ende A, Kuijpers TW. Epidemiologic and microbiologic characteristics of recurrent bacterial and fungal meningitis in the Netherlands, 1988-2005. Clin Infect Dis 2008; 47:e42 - 51; http://dx.doi.org/10.1086/590251; PMID: 18643757
   PubMedGoogle Scholar
• Bruge J, Bouveret-Le Cam N, Danve B, Rougon G, Schulz D. Clinical evaluation of a group B meningococcal N-propionylated polysaccharide conjugate vaccine in adult, male volunteers. Vaccine 2004; 22:1087 - 96; http://dx.doi.org/10.1016/j.vaccine.2003.10.005; PMID: 15003635
   PubMed Web of Science ®Google Scholar
• Wyle FA, Artenstein MS, Brandt BL, Tramont EC, Kasper DL, Altieri PL, et al. Immunologic response of man to group B meningococcal polysaccharide vaccines. J Infect Dis 1972; 126:514 - 21; http://dx.doi.org/10.1093/infdis/126.5.514; PMID: 4197754
   PubMed Web of Science ®Google Scholar
• Jelfs J, Munro R, Wedege E, Caugant DA. Sequence variation in the porA gene of a clone of Neisseria meningitidis during epidemic spread. Clin Diagn Lab Immunol 2000; 7:390 - 5; PMID: 10799451
   PubMedGoogle Scholar
• Martin DR, Ruijne N, McCallum L, O’Hallahan J, Oster P. The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB. Clin Vaccine Immunol 2006; 13:486 - 91; http://dx.doi.org/10.1128/CVI.13.4.486-491.2006; PMID: 16603616
   PubMed Web of Science ®Google Scholar
• Tondella ML, Popovic T, Rosenstein NE, Lake DB, Carlone GM, Mayer LW, et al, The Active Bacterial Core Surveillance Team. Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. J Clin Microbiol 2000; 38:3323 - 8; PMID: 10970378
   PubMed Web of Science ®Google Scholar
• Madico G, Welsch JA, Lewis LA, McNaughton A, Perlman DH, Costello CE, et al. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol 2006; 177:501 - 10; PMID: 16785547
   PubMed Web of Science ®Google Scholar
• Schneider MC, Exley RM, Chan H, Feavers I, Kang YH, Sim RB, et al. Functional significance of factor H binding to Neisseria meningitidis. J Immunol 2006; 176:7566 - 75; PMID: 16751403
   PubMed Web of Science ®Google Scholar
• Murphy E, Andrew L, Lee KL, Dilts DA, Nunez L, Fink PS, et al. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis 2009; 200:379 - 89; http://dx.doi.org/10.1086/600141; PMID: 19534597
   PubMed Web of Science ®Google Scholar
• Jiang HQ, Hoiseth SK, Harris SL, McNeil LK, Zhu D, Tan C, et al. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine 2010; 28:6086 - 93; http://dx.doi.org/10.1016/j.vaccine.2010.06.083; PMID: 20619376
   PubMed Web of Science ®Google Scholar
• Fletcher LD, Bernfield L, Barniak V, Farley JE, Howell A, Knauf M, et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun 2004; 72:2088 - 100; http://dx.doi.org/10.1128/IAI.72.4.2088-2100.2004; PMID: 15039331
   PubMed Web of Science ®Google Scholar
• Borrow R, Carlone GM, Rosenstein N, Blake M, Feavers I, Martin D, et al. Neisseria meningitidis group B correlates of protection and assay standardization--international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005. Vaccine 2006; 24:5093 - 107; http://dx.doi.org/10.1016/j.vaccine.2006.03.091; PMID: 16838413
   PubMed Web of Science ®Google Scholar
• Marshall H, Nissen MD, Richmond P, Lambert SB, Roberton D, Gruber W, et al. A Randomized, Plaebo-Controlled, Double-Blind, Phase 1 Trial of Ascending Doses of Meningococcal Group B rLP2086 Vaccine in Healthy Adults. Rotterdam, The Netherlands: Presented at the Sixteenth International Pathogenic Conference, 2008.
   Google Scholar
• Marshall H, Richmond P, Nissen MD, Jiang Q, Anderson A, Jansen KU, et al. Phase 1 Randomized Controlled Clinical Trial of Safety and Immunogenicity of a Meningococcal B Bivalent Vaccine in Healthy Toddlers. The Hague, The Neatherlands: Presented at the Twenty-ninth Annual Meeting of the European Society for Paediatric Infectious Diseases, 2011.
   Google Scholar
• Richmond P, Marshall H, Nissen M, Jiang Q, Jansen KU, Garces-Sanchez M, et al. Phase 2 Randomised Controlled Trial of Safety and Immunogenicity of a Meningococcal B Bivalent Vaccine (rLP2086) in Healthy Adolescents. The Hague, The Netherlands: Presented at the Twenty-ninth Annual Meeting of the European Society for Paediatric Infectious Diseases, 2011.
   Google Scholar
• Gossger N, Snape MD, Yu LM, Finn A, Bona G, Esposito S, et al, European MenB Vaccine Study Group. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA 2012; 307:573 - 82; http://dx.doi.org/10.1001/jama.2012.85; PMID: 22318278
   PubMed Web of Science ®Google Scholar
• Santolaya ME, O’Ryan ML, Valenzuela MT, Prado V, Vergara R, Muñoz A, et al, V72P10 Meningococcal B Adolescent Vaccine Study group. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet 2012; 379:617 - 24; http://dx.doi.org/10.1016/S0140-6736(11)61713-3; PMID: 22260988
   PubMed Web of Science ®Google Scholar
• Ala’aldeen DA, Flint M, Oldfield NJ, Omer SA, McNeil LK, Jiang Q, et al. Human antibody responses to the meningococcal factor H binding protein (LP2086) during invasive disease, colonization and carriage. Vaccine 2010; 28:7667 - 75; http://dx.doi.org/10.1016/j.vaccine.2010.09.038; PMID: 20875489
   PubMed Web of Science ®Google Scholar